Annexon Biosciences Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
71
- Stock Symbol
-
ANNX
- Share Price
-
$7.03
- (As of Thursday Closing)
Annexon Biosciences General Information
Description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Contact Information
Website
www.annexonbio.comCorporate Office
- 1400 Sierra Point Parkway
- Building C, 2nd Floor
- Brisbane, CA 94005
- United States
Corporate Office
- 1400 Sierra Point Parkway
- Building C, 2nd Floor
- Brisbane, CA 94005
- United States
Annexon Biosciences Timeline
Annexon Biosciences Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.03 | $6.93 | $1.57 - $8.40 | $742M | 106M | 1.4M | -$1.21 |
Annexon Biosciences Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 282,366 | 221,601 | 10,436 | 203,383 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (124,791) | (141,575) | (143,493) | (128,572) |
| Net Income | (115,159) | (134,237) | (141,947) | (130,323) |
| Total Assets | 406,085 | 297,674 | 285,096 | 287,040 |
| Total Debt | 30,203 | 31,355 | 32,858 | 34,589 |
Annexon Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Annexon Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Annexon Biosciences Comparisons
Industry
Financing
Details
000000
000000
Annexon Biosciences Competitors (72)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alector | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| Vedanta Biosciences | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 0000000000 | 00000 |
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000000 | 00000 |
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. | |
| Alzheon | Venture Capital-Backed | Framingham, MA | 00 | 00000 | 00000000000 | 00000 |
Annexon Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Annexon Biosciences Patents
Annexon Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230265109-A1 | Inhibitors of complement factors and uses thereof | Pending | 14-Jan-2022 | 00000000 | 0 |
| AU-2023207988-A1 | Inhibitors of complement factors and uses thereof | Pending | 14-Jan-2022 | 00000000 | |
| AU-2022425559-A1 | Compositions and methods for treating huntington's disease | Pending | 30-Dec-2021 | 000000000 | |
| US-20230279103-A1 | Anti-complement factor c1q antibodies with single binding arms and uses thereof | Pending | 13-Dec-2021 | 000000000 | |
| EP-4419144-A1 | Compositions and methods for treating muscular dystrophy | Pending | 21-Oct-2021 | A61P21/00 |
Annexon Biosciences Executive Team (13)
| Name | Title | Board Seat |
|---|---|---|
| Douglas Love JD | Chief Executive Officer & Board Member | |
| Jennifer Lew | Chief Financial Officer & Executive Vice President | |
| Dean Artis Ph.D | Chief Scientific Officer | |
| Larry Mattheakis Ph.D | Chief Scientific Officer | |
| Ted Yednock Ph.D | Executive Vice President & Chief Innovation Officer |
Annexon Biosciences Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Douglas Love JD | Annexon Biosciences | Chief Executive Officer & Board Member | 000 0000 |
| Jung Choi | Self | Board Member | 000 0000 |
| Muneer Satter JD | Satter Foundation | Board Member | 000 0000 |
| Ricky Sun Ph.D | Bain Capital | Board Member | 000 0000 |
| Thomas Wiggans | Self | Chairman & Board Member | 000 0000 |
Annexon Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Annexon Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Annexon Biosciences ESG
Risk Overview
Risk Rating
Updated January, 24, 2024
33.47 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
Annexon Biosciences FAQs
-
When was Annexon Biosciences founded?
Annexon Biosciences was founded in 2007.
-
Who is the founder of Annexon Biosciences?
Ben Barres Ph.D and Arnon Rosenthal Ph.D are the founders of Annexon Biosciences.
-
Who is the CEO of Annexon Biosciences?
Douglas Love JD is the CEO of Annexon Biosciences.
-
Where is Annexon Biosciences headquartered?
Annexon Biosciences is headquartered in Brisbane, CA.
-
What is the size of Annexon Biosciences?
Annexon Biosciences has 71 total employees.
-
What industry is Annexon Biosciences in?
Annexon Biosciences’s primary industry is Biotechnology.
-
Is Annexon Biosciences a private or public company?
Annexon Biosciences is a Public company.
-
What is Annexon Biosciences’s stock symbol?
The ticker symbol for Annexon Biosciences is ANNX.
-
What is the current stock price of Annexon Biosciences?
As of 19-Sep-2024 the stock price of Annexon Biosciences is $7.03.
-
What is the current market cap of Annexon Biosciences?
The current market capitalization of Annexon Biosciences is $742M.
-
Who are Annexon Biosciences’s competitors?
Alector, Vedanta Biosciences, Rhythm Pharmaceuticals, Sorrento Therapeutics, and Alzheon are some of the 72 competitors of Annexon Biosciences.
-
What is Annexon Biosciences’s annual earnings per share (EPS)?
Annexon Biosciences’s EPS for 12 months was -$1.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
